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Abstract
Objective Our aim was to assess the prevalence of endocrine paraneoplastic syndromes (EPNS) in neuroendocrine neo-
plasms (NENs) and estimate its impact on patient outcomes.
Design This is a retrospective analysis of 834 patients with NENs (611 gastrointestinal, 166 thoracic, 57 of unknown and various
other primary origin). We included 719 consecutive NEN patients treated at EKPA-Laiko Hospital, Athens, Greece and 115 patients
with lung carcinoid (LC) treated at Uppsala University Hospital, Uppsala, Sweden. EPNS diagnosis was based on standard criteria.
Methods Twenty-one patients with EPNS were detected: 16 with ectopic Cushing’s syndrome (ECS), one with hypercal-
caemia due to parathyroid hormone-related protein (PTHrP) secretion, three with hypercalcitonaemia and one patient with
dual secretion of calcitonin and beta-human chorionic gonadotropin (β-HCG). All tumours were well-differentiated; 10
patients had Stage IV disease at diagnosis.
Results The prevalence of EPNS in the Greek cohort was 1.9%, whereas that of ECS among LC patients in both centres was
6.7%. Median overall survival (OS) for patients with EPNS was 160.7 months (95%CI, 86–235.4) and median event-free
survival (EFS) was 25.9 months (95%CI, 0–57.2). Patients presenting with EPNS prior to NEN diagnosis had longer EFS
compared to patients with synchronous or metachronous EPNS (log-rank P= 0.013). Patients with ECS of extra-thoracic
origin demonstrated shorter OS and EFS compared to patients with ECS of lung or thymic origin (log-rank P= 0.001 and P
< 0.001, respectively). LC patients with and without ECS were comparable in 5-year and 10-year OS rates (66.7% and
33.3% versus 89.8% and 60.2%, respectively; 95%CI [189.6–300.4 months], log-rank P= 0.94) and in median EFS, 67
versus 183 months, 95%CI [50.5–207.5], log-rank P= 0.12).
Conclusion EPNS are relatively rare in patients with NENs and mainly concern well-differentiated tumours of the foregut.
Among patients with EPNS, LC-related ECS may not adversely affect patient outcomes when diagnosed prior to NEN and
effectively been treated.
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Introduction
Paraneoplasmatic syndromes (PNS) can be produced by
peptides, amines or cytokines secreted by the tumour, or by
immune cross-reactivity between neoplastic and normal
tissues, and originate from either endocrine or non-
endocrine neoplasms [1]. Neoplasms that cause endocrine
PNS (EPNS) exhibit a wide range of malignant potential,
ranging from benign to highly malignant tumours. The
majority of EPNS is produced from non-endocrine neo-
plasms and are found in tumours with an adverse biological
behaviour, involving the lungs, breast, prostate, ovaries,
skin, as well as certain haematological neoplasias [2–6].
Generally, in highly malignant neoplasms, disease prog-
nosis is determined from the biological behaviour of the
underlying malignancy rather than the related EPNS
manifestations.
Neuroendocrine neoplasms (NENs) have also been
associated with EPNS [7]. These neoplasms comprise a
heterogeneous group of mostly well-differentiated tumours
with a generally favourable prognosis. They can often be
“functioning”, i.e. they share the ability to synthesise and
secrete bioactive substances characteristic of the cell of
origin that may cause distinct clinical syndromes [8]. In
contrast, EPNS constitute a distinct array of manifestations
that cannot be attributed to a secreting neoplastic lesion
related to the originating anatomical site. Thus, the secretion
of bioactive substances is considered ectopic. A large
number of different EPNS secondary to NENs has been
reported, exhibiting clinical signs and symptoms that are
similar to those caused when the secretory product is
derived from the expected site of origin [9].
Importantly, EPNS might complicate the patient’s clin-
ical course and response to therapy, and may potentially
impact prognosis. Occasionally, EPNS manifest themselves
prior to the diagnosis of the underlying neoplasia [10].
However, the development of EPNS does not always cor-
relate with tumour stage, grade, and patient outcomes [11].
Thus, the prognostic impact of EPNS in NENs remains to
be elucidated further, particularly as there is an increment in
the number of NENs diagnosed compared to other
neoplasias.
To date, systemic documentation of NEN-related EPNS
although is increasingly been recorded still remains rather
limited and relevant studies are widely dispersed [9, 12–15].
The aim of this study was to record EPNS secondary to
NENs and to provide information regarding EPNS pre-
valence, clinical presentation and impact on overall
prognosis in patients with NENs. As previous studies have
suggested that EPNS are more prevalent in lung compared
to other NENs, we opted to address this particular issue by
including a large number of such neoplasms.
Subjects and methods
The diagnoses were made between 1994 and 2017 and
patients were followed until death or the 1 May 2018.
Demographics [age, gender] as well as disease character-
istics (type and timing of EPNS in relation to NEN diag-
nosis, NEN type, stage and grade, immunohistochemical
marker status, serum biomarkers status, octreoscan/(68)Ga-
DOTATATE positron emission tomography (PET) and 18F-
ﬂuorodeoxyglucose (FDG)-PET positivity) were registered.
NEN progression was assessed radiologically according to
the Response Evaluation Criteria in Solid Tumours
(RECIST 1) [16]. In order to assess the impact of EPNS on
overall prognosis in patients with NENs, event-free survival
(EFS) was calculated from the NEN diagnosis for patients
exhibiting disease recurrence or progression. For the subset
of patients receiving several lines of treatments, we assessed
recurrence or progression in relation to the ﬁrst line of
treatment, which mainly consisted of resective surgery. The
presence of EPNS was recorded either prior to or at NEN
diagnosis (synchronous) or subsequently during the course
of the follow-up (metachronous). For ECS diagnosed prior
to the identiﬁcation of the ectopic tumoural source of
adrenocorticotropic hormone (ACTH), the syndrome is
deﬁned as overt when it is followed by a prompt identiﬁ-
cation of the tumoural source and covert when the tumour is
identiﬁed during a subsequent evaluation or a prolonged
follow-up [17].
The study was conducted according the 1975 Declaration
of Helsinki and approved by the regional ethics review
boards in Athens, Greece, and Uppsala, Sweden. Written
informed consent was obtained from all the study partici-
pants. To ensure the quality of data reporting, we followed
the STROBE statement [18].
Diagnosis of NEN and EPNS
Diagnosis of NEN was made on the basis of histopatholo-
gical conﬁrmation, cross-sectional and functional imaging.
The role of the serum biomarker Chromogranin-A in NEN
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diagnosis was supplementary. EPNS diagnosis was made
according to standard criteria as presented in Supplementary
Table 3 [19]. Speciﬁcally, the parathyroid hormone-related
protein (PTHrP) hypersecretion diagnosis was based on
persistent hypercalcaemia and suppressed plasma PTH
levels in combination with elevated plasma PTHrP levels.
Cushing’s syndrome secondary to ectopic ACTH secretion
(ectopic Cushing’s syndrome (ECS)] was deﬁned as
ACTH-dependent hypercortisolaemia in patients with
tumours known to be associated with ectopic ACTH
secretion, and was substantiated with further endocrine tests
that suggested an ectopic source and/or positive ACTH
immunostaining of non-pituitary tumours. Hypercalcito-
naemia EPNS diagnosis was based on plasma elevation of
calcitonin >10 pg/ml in patients with tumours known to be
associated with ectopic calcitonin secretion, exclusion of
other conditions related to high calcitonin levels (including
normal thyroid ultrasound), presence of symptoms not
attributed to the secretion of another measurable bioactive
compound (ﬂushing and/or diarrhoea) and positive calcito-
nin immunostaining of non-thyroid NENs.
Carcinoid syndrome is rare in patients with pancreatic
NEN (panNEN), but serotonin secretion may occur, as
demonstrated by elevated urinary 5-hydroxyindoleacetic
acid (U-5-HIAA) levels [20]. However, in this setting ser-
otonin secretion is considered as eutopic; thus patients with
panNENs and elevated 5-HIAA levels were not included in
this study [20].
Patients regularly underwent cross-sectional imaging
with computed tomography (CT) or magnetic resonance
tomography (MRT), and functional imaging with soma-
tostatin receptor scintigraphy and/or PET using different
tracers, both at baseline and during follow-up, in order to
assess tumour load and to evaluate treatment effects and
disease recurrence or progression as indicated per patient.
Patients with NENs were screened at diagnosis for
eutopic hormone secretion according to the site of origin,
i.e. C-peptide, gastrin, glucagon, insulin, pancreatic poly-
peptide, pro-insulin, VIP, 24-h U-5-HIAA and chromo-
granin A for panNENs.
U-5-HIAA and chromogranin A were also evaluated in
patients with LCs and small intestinal NENs. Patients with
other NENs as well as NENs of unknown primary from the
Greek database (EKPA-Laiko) underwent extensive hor-
monal screening, including beta human chorionic gonado-
tropin (β-HCG). All patients with panNENs, LCs, thymic
carcinoids and UPO NENs were screened for calcitonin at
diagnosis. However, ectopic hormonal screening was not
performed on a regular basis during follow-up, but as
indicated per patient on the basis of relevant clinical and
biochemical ﬁndings. ACTH, plasma and 24-h urinary
cortisol were analysed when Cushingoid symptoms/signs
were present. PTHrP was evaluated only in cases with
hypercalcaemia, whereas other hormones were evaluated in
the presence of suggestive symptoms. When different
assays of the same hormone were employed over the time
period of the study, values were converted to relative units.
We used the 2017 and 2015 WHO classiﬁcation systems
for grading of gastroenteropancreatic NENs and thoracic
NENs (thymic and lung carcinoids), respectively [21, 22].
Accordingly, for staging, the 8th edition of the American
Joint Committee on Cancer (AJCC) and the revised 8th
edition of Thoracic Neoplasms Stage Classiﬁcation were
used [23, 24].
As NENs of thoracic origin (lung and thymic) are related
to frequencies as high as 45% of ECS prevalence secondary
to NENs [15], we performed a separate analysis regarding
primary and secondary end-points in this particular group.
Statistics
All statistical analyses (frequencies, descriptive statistics,
Kaplan–Meier curves, log-rank tests] were done with the
SPSS 23.0 software package [IBM SPSS Statistics,
Armonk, NY, USA). Overall and EFS were analysed using
Kaplan–Meier methods. Log-rank testing (Mantel–Cox)
was used to determine whether there was a difference
between mortality and disease recurrence or progression in
NEN patients with EPNS, stratiﬁed by EPNS type and
timing, origin of the primary tumour, as well as within the
subset of LC patients with ECS compared with the Swedish
cohort of LC patients, with complete follow-up data. Tests
were two-sided and P-value < 0.05 was considered statisti-
cally signiﬁcant.
Results
From a total of 834 NEN patients, 21 patients (9 women,
42.9%) met the diagnostic criteria of EPNS (Supplementary
Table 2). Sixteen patients presented with ECS (76.2% of
EPNS), one patient had hypercalcaemia due to PTHrP
secretion, three patients had hypercalcitonaemia in the
absence of thyroid disease, and one male patient demon-
strated dual ectopic secretion of calcitonin and β-HCG. The
prevalence of EPNS in the Greek cohort of NENs was 1.9%
(14/719), whereas the prevalence of ECS among patients
with LCs in both centres was 6.7% (11/164). ECS was the
main EPNS detected in our series (Table 1).
All tumours were well differentiated (5G1, 15G2 and
1G3) and none occurred in a familial setting. Nine patients
presented with Stage IV disease, including all four patients
with hypercalcitonaemia and the patient with hypercalcae-
mia due to PTHrP secretion. Within the subset of LC
patients (n= 12), seven tumours had atypical histopathol-
ogy; one patient had hypercalcitoneamia, whereas 11
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patients manifested ECS. ECS was of thoracic origin in 12
patients (11 lung/1 thymic) and extra-thoracic origin in four
patients (2 pancreatic NENs (panNENs)/1 small intestinal
NEN/1 NEN of unknown primary origin). In those patients
with LC-related ECS, one presented with stage IV disease,
whereas the remaining 10 patients as well as the one patient
with thymic-related ECS presented at stages I–III. PanNENs
were involved in three different EPNS with a prevalence of
1.9% (5/265) and were mainly disseminated at diagnosis (4/
5). The different NEN sources of EPNS are presented in
Table 1.
The median age at NEN diagnosis was 56 years (range:
25–75) whereas the diagnosis of EPNS was synchronous in
six patients, metachronous in ﬁve patients and prior to the
NEN diagnosis in the remaining 10 patients, all of whom
presented with ECS (six overt and four covert ECS cases,
Table 1, Supplementary Figure 1).
Median follow-up was 89.6 months [range
5–236 months]. Median overall survival (OS) for NEN
patients with EPNS was 160.7 months (95%CI, 86–235.4)
and median EFS was 25.9 months (95%CI, 0–57.2).
Patients with different types of EPNS (ECS versus other
EPNS types) were comparable in OS and EFS (log-rank P
= 0.851 and 0.683, respectively, Fig. 1). Patients presenting
with EPNS prior to NEN diagnosis had longer EFS com-
pared to patients with synchronous or metachronous EPNS
(log-rank P= 0.013, Fig. 2). Within the subset of LCs,
patients with and without ECS were comparable in 5-year
and 10-year OS rates (66.7% and 33.3% versus 89.8% and
60.2%, respectively; 95%CI [189.6–300.4 months], log-
rank P= 0.94), as well as in the median (EFS 67 versus
183 months; 95%CI [50.5–207.5], log-rank P= 0.12, Fig.
3). However, patients with ECS of extra-thoracic origin
demonstrated shorter OS and EFS compared to patients
with ECS of lung or thymic origin (log-rank P= 0.001 and
P < 0.001, respectively).
All patients underwent cross-sectional imaging at diag-
nosis of NEN disease with nine patients having Stage IV
disease at baseline, whereas six patients were diagnosed at
Stage I, three patients at Stage II and three patients at Stage
III. Only one patient with EPNS prior to the NEN diagnosis
had Stage IV disease at baseline. Functional imaging
undertaken at baseline and/or during the NEN disease
course demonstrated that 12 patients had uptake on
octreotide scintigraphy or 68 Gallium PET imaging,
whereas nine patients were negative. A subset of eight
patients underwent FDG-PET imaging, exhibiting tracer
uptake in ﬁve cases (Table 1).
All 12 patients with up to Stage III disease underwent
surgery with the intention to cure and/or control the ectopic
hormonal excess. Two patients with distant stage disease
underwent debulking surgery to control EPNS (Supple-
mentary Table 3). Eight patients with ECS, all of whom
with NENs of thoracic origin, underwent bilateral adrena-
lectomy in order to control hypercortisolaemia early in the
disease course. Anti-proliferative treatments including
somatostatin analogues (SSA), systemic chemotherapy and
targeted therapies were used as indicated during the disease
course (Supplementary Table 3). Additionally, symptomatic
Table 1 Patient characteristics at diagnosis
Sex ratio (M:F) 8:5
Median age at diagnosis (years) 56 (range: 25-75)
EPNS type
Ectopic Cushing’s syndrome 16
Hypercalcitonemia 4
Hypercalcemia due to PTHrP secretion 1
Ectopic β-HCG secretion 1
Site of primary
Small intestine 1
Pancreas 5
Lung (histopathological type) 13 (7 typical/ 6
atypical)
Thymic 1
Unknown 2
Syndromic:sporadic ratio 0:21
TNM stage at diagnosis
I 6
II 3
III 3
IV 9
WHO grade
G1 5
G2 15
G3 1
Timing of ePNS in relation to NEN diagnosis
Prior (overt:covert ratio) 10 (6:4)
Synchronous 6
Metachronous 5
Immunohistochemical positivity
ACTH 14
Calcitonin 4
PTHrP 1
β-HCG 1
Serum biomarker elevation
ACTH 16
Calcitonin 4
PTHrP 1
β-HCG 1
Octreoscan/68Gallium-PET (positive:negative
ratio)
12:9
FDG-PET (positive:negative:not performed
ratio)
5:3:13
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treatments, (e.g. intravenous (IV) ﬂuids, bisphosphonates
(IV) and cinacalcet in the case of hypercalcaemia due to
PTHrP secretion, and ketoconazole/metyrapone in six cases
with ECS), were given as indicated. Generally, variable
effects for different lines of treatment in terms of controlling
hormonal excess were achieved (Fig. 4). In the majority of
patients, hormone over-secretion was related to disease
recurrence or progressive disease.
Fig. 1 a Overall survival and b event-free survival analysis of patients with paraneoplastic endocrine syndromes (EPNS) secondary to neu-
roendocrine neoplasms stratiﬁed by type of EPNS
Fig. 2 a Overall survival and b event-free survival analysis of patients with paraneoplastic endocrine syndromes secondary to neuroendocrine
neoplasms stratiﬁed by timing of diagnosis
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Discussion
In this study, the prevalence of the EPNS secondary to a
variety of NENs as obtained from the Greek NEN database
(EKPA-Laiko) was found to be 1.9% and included ﬁve
different syndromes. In contrast, EPNS was more prevalent
in patients with LCs (6.7%) in both centres and was mainly
related to ECS. PanNENs exhibited the largest diversity, as
they were involved in three EPNS with a prevalence of
1.9%. All patients with EPNS secondary to NENs were
related to well-differentiated tumours, with the majority
presenting with Grade 2 disease. Atypical histopathological
ﬁndings were prevalent among patients with ECS secondary
to LC (7/12). In contrast to ECS, where the majority of
patients had locoregional disease at diagnosis mostly
attributed to lung NENs, all patients with hypercalcitonae-
mia, PTHrP and/or β-HCG secretion had Stage IV disease.
The diagnosis of EPNS was synchronous in six patients,
metachronous in ﬁve patients and preceded the NEN diag-
nosis in the remaining 10 patients, with the latter only
related to ECS, mainly of LC origin (9/10). Elevated ectopic
hormone secretion was related to disease recurrence or
progression in the majority of patients. The response to
treatment in relation to secretory syndromes varied greatly
among the patients included in the study. In the single
patient with hypercalcaemia due to PTHrP secretion, sur-
gery, multiple anti-proliferative treatments and symptomatic
therapy with IV ﬂuids, biphosphonate and cinacalcet con-
trolled the secretory symptoms adequately. Resective sur-
gery, when feasible, combined with anti-proliferative/
symptomatic treatments as indicated per patient, and
occasional bilateral adrenalectomy, achieved control of the
hypercortisolaemia.
Interestingly, patients presenting with EPNS prior to
their NEN diagnosis had longer EFS compared to patients
with synchronous or metachronous EPNS. Importantly,
ECS of extra-thoracic origin was more often synchronous or
metachronous, and exhibited worse prognosis compared to
patients with ECS of lung or thymic origin. In particular, the
diagnosis of ECS was overt or covert in many cases (10/16),
facilitating diagnosis of NEN at an earlier stage, mostly
regarding LC-related ECS. Indeed, a minority of four
patients (4/16) with ECS had Stage IV disease at diagnosis,
only one of whom had LC-related ECS.
Generally, mortality rates might be increased in patients
with ECS and uncontrollable hypercortisolaemia, partly due
to susceptibility to infection and thromboembolic episodes
[15, 25–28]. This increased mortality risk was not con-
ﬁrmed in patients with LC-related ECS of our study, as
comparable OS and EFS rates were evident between LC
patients with and without ECS. This was possibly due to
overrepresentation of LC patients with early-stage disease
(I–III) and mild-related hypercortisolism, who underwent
curative surgery early in the disease course. On the contrary,
dismal outcomes were clearly evident in the few cases of
ECS of extra-thoracic origin that was presented at stage IV
with synchronous or metachronous ECS.
Although elevated calcitonin is a marker of medullary
thyroid carcinoma (MTC), it may be ectopically produced
and can be elevated in other NENs, particularly those ori-
ginating from the foregut. The immunohistochemical and
morphologic proﬁle of calcitonin-secreting NENs may be
Fig. 3 a Overall survival and b event-free survival analysis of lung carcinoid patients with and without ectopic Cushing’s syndrome
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indistinguishable from MTC [14]. Presenting symptoms
related to hypercalcitoninaemia may include profound
diarrhoea, metabolic alkalosis with hypokalaemia, hypo-
calcaemia, hypomagnesaemia, hypophosphataemia and
hyperglycaemia [29]. In the majority of cases in the litera-
ture, hypercalcitonaemia is not associated with a secretory,
clinically apparent syndrome. In our study, all four cases
detected with hypercalcitonaemia were described together
with other EPNS diagnoses. These patients manifested
diarrhoea and ﬂushing at some point and had no other
measurable bioactive hormonal secretion. However, the
main mechanism of diarrhoea in these patients maybe a
shortened colonic transit time resulting in decreased
absorption, rather than a direct calcitonin-induced small
intestinal ﬂuid secretion [30]. Importantly, all the patients
with ectopic secretion of calcitonin had disseminated dis-
ease at diagnosis.
Ectopic hypersecretion of PTHrP by NENs is indeed
rare, as demonstrated in our study, and seems to be asso-
ciated exclusively with metastatic panNENs in accordance
with previous reports [13]. PTHrP production may also
have a major clinical impact due to poorly controllable
hypercalcaemia with increased associated morbidity and
mortality. The single case with ectopic PTHrP secretion
included in our study required aggressive multimodal
treatment in order to control the hypercalcaemia.
Ectopic β-HCG secondary to thoracic tumours (mainly
SCLCs, carcinoids and extragonadal germ cell tumours),
clear cell renal tumours or liver carcinomas, may, on rare
occasions, induce gynaecomastia in men, menstrual irre-
gularity and virilisation in women, and precocious puberty
in children [19]. In our study, one male patient with a pri-
mary of unknown origin demonstrated dual secretion of
calcitonin and β-HCG that was not associated with overt
clinical symptoms. Thus, β-HCG was regardered as biolo-
gically active, as gonadotrophin levels were suppressed in
the presence of high testosterone levels and recovered fol-
lowing successful treatment of the neoplasm and sub-
sequent normalisation of β-HCG levels. Additionally, IHC
staining of metastatic lesions in the liver was positive for β-
HCG, calcitonin, synaptophysin and Chromogranin A.
Importantly, apart from NENs of unknown primary ori-
gin, EPNS were mainly present in NENs of the foregut, i.e.
panNENs, LCs and thymic carcinoids, with the exception of
one patient with ECS secondary to a small intestinal neu-
roendocrine tumour. PanNENs in particular were involved
Fig. 4 XY plots on different ePNS with patient examples. a ECS
hormonal status [ACTH (pg/ml), urinary-free cortisol (UFC, pg/g
creatinine)]) over time. b Ectopic PTHrP secretion and plasma calcium
concentration [PTHrP (pg/ml), plasma calcium (mg/dl)]) over time. c
VIP hormonal status (pmol/l) over time. d Calcitonin (pg/ml) hor-
monal status over time
Endocrine
in a diverse spectrum of three different EPNS and were
often disseminated at diagnosis. This is in accordance with
the diversity of panNEN hormone secretion at a late stage
and the extreme scarcity of EPNS secondary to midgut
tumours, in particular small intestinal NENs as reported by
Crona et al. in a study on multiple and secondary hormone
secretion from gastroentero-pancreatic NENs [31].
In the majority of patients, hormone oversecretion was
related to disease recurrence or progressive disease. Thus,
plasticity of the associated ectopically produced hormones
during follow-up may be useful as prognostic and predictive
markers. In ECS, ACTH and cortisol levels were also
affected by anti-hormonal treatments and bilateral adrena-
lectomy. Hence, response to anti-proliferative treatments
was rather poorly depicted in cortisol and ACTH levels (Fig.
4A). As the prevalence of EPNS is relatively low, it mainly
concerns NENs of the foregut; and with regards to LC-
related ECS no clear association to unfavourable prognosis
was evident in our series, we cannot advocate in favour of
routine screening for EPNS in NEN patients. Nevertheless, a
multidisciplinary approach within a specialised referral
centre for NENs is crucial and should be considered standard
of care for all NEN patients, as it may even facilitate early
EPNS detection and implementation of multimodal indivi-
dualised treatment plans in such complex cases.
Our study has some limitations. The scarcity of EPNS
secondary to NENs combined with the long OS of NEN
patients makes any effort to undertake a prospective ran-
domised study on patient outcomes virtually impossible.
Indeed, due to the small sample size of this study, survival
analysis ﬁndings should be interpreted with caution, pre-
cluding safe conclusions to be derived. NEN heterogeneity,
treatment factors, such as the quality of surgery in different
centres, differences in systemic therapies as well as multiple
treatments, may all have confounded the results. Ectopic
hormonal screening was not performed on a regular basis,
but as indicated per patient according to the existing
guidelines. Thus, the results may differ from prospectively
collected data, and the prevalence of EPNS causing s sub-
clinical symptomatology may have been underestimated.
This study is also limited by a referral bias to the two ter-
tiary centres involved. Some of these drawbacks are, of
course, inherent to any retrospective multicentre study.
However, the strength of this study is that it provides a
comprehensive epidemiologic picture of NEN associated
with rare EPNS with a prevalence assessment and a special
focus on LC-related ECS. Additionaly, it demonstrates that
timing of EPNs diagnosis and origin of the primary
tumoural source may impact NEN prognosis.
Systematic documentation and registration of these syn-
dromes in national databases and international collabora-
tions between referral centres may increase awareness and
further elucidate several aspects of EPNS. In particular,
recent diagnostic and therapeutic advances in the ﬁeld of
NENs, might help to clearly delineate EPNS in NENs, shed
light to EPNS pathogenesis, facilitate earlier tumour/EPNS
diagnosis, improve patient outcomes by individualised
therapeutic choices and possibly avoid unnecessary
screening and associated costs by implementing surveil-
lance approaches as clinically indicated per patient.
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